Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AARON MILSTONE

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1134211550
CMS profile
232262
Location
FRANKLIN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$116,376.14

146 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AARON MILSTONE

NPI 1134211550 · CMS profile ID 232262

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

FRANKLIN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134211550?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AARON MILSTONE, NPI 1134211550, CMS profile ID 232262. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134211550?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). AARON MILSTONE, NPI 1134211550, CMS profile ID 232262. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134211550?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
AARON MILSTONE, NPI 1134211550, CMS profile ID 232262, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1134211550?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

146 matching records · $116,376.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 146 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 146.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $18.6508/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738533911 CMS
Mylan Specialty L.P. $1,064.0008/12/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751385617 CMS
Mylan Specialty L.P. $74.2508/01/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751388377 CMS
AstraZeneca Pharmaceuticals LP $31.9007/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736086163 CMS
Insmed, Inc. $5.0407/07/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739693899 CMS
GlaxoSmithKline, LLC. $1,200.0006/30/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738578087 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.7606/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720491263 CMS
GlaxoSmithKline, LLC. $1,200.0006/16/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738627777 CMS
GlaxoSmithKline, LLC. $14.1706/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738798669 CMS
Mylan Specialty L.P. $750.0006/01/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751388361 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.2405/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720491267 CMS
Grifols USA, LLC $20.5005/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750411031 CMS
GlaxoSmithKline, LLC. $1,200.0005/19/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738534637 CMS
Insmed, Inc. $20.9505/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739693983 CMS
Mylan Specialty L.P. $349.0505/17/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751408259 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.9005/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720491271 CMS
Sunovion Pharmaceuticals Inc. $11.8205/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748397143 CMS
United Therapeutics Corporation $12.7005/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752463547 CMS
GlaxoSmithKline, LLC. $19.7905/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738936905 CMS
Actelion Pharmaceuticals US, Inc. $33.4204/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718926569 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $4,008.0004/24/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720985649 CMS
Insmed, Inc. $25.9304/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739690321 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,025.0004/09/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720491295 CMS
GlaxoSmithKline, LLC. $1,200.0004/07/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738588781 CMS
Mylan Specialty L.P. $2,025.0004/01/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751390501 CMS
GlaxoSmithKline, LLC. $16.4403/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738795801 CMS
Mylan Specialty L.P. $795.0003/26/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751383749 CMS
Mylan Specialty L.P. $795.0003/26/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751383913 CMS
Genentech USA, Inc. $3,720.0003/05/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742971495 CMS
Genentech USA, Inc. $124.6403/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742971503 CMS
Genentech USA, Inc. $555.0603/05/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742971508 CMS
GlaxoSmithKline, LLC. $1,200.0003/05/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738535389 CMS
Resmed Corp $14.7903/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751836293 CMS
Mylan Specialty L.P. $2,025.0003/01/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751385145 CMS
GlaxoSmithKline, LLC. $900.0002/24/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738732785 CMS
Pulmonx Corporation $14.0002/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719698721 CMS
Mylan Specialty L.P. $2,120.0002/20/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751383241 CMS
Mylan Specialty L.P. $193.7002/20/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751383243 CMS
Mylan Specialty L.P. $117.9402/20/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751383549 CMS
Mylan Specialty L.P. $874.5002/20/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751403001 CMS
Insmed, Inc. $9.5902/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739692325 CMS
Insmed, Inc. $93.0002/18/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739693209 CMS
GlaxoSmithKline, LLC. $19.0802/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738789543 CMS
Insmed, Inc. $540.1002/15/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739691353 CMS
Insmed, Inc. $770.0002/15/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739691595 CMS
Insmed, Inc. $232.9602/14/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739691523 CMS
Insmed, Inc. $131.3202/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739691677 CMS
Mylan Specialty L.P. $2,120.0002/13/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751404047 CMS
Insmed, Inc. $12.3402/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739691229 CMS
Insmed, Inc. $125.0002/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739694479 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $210,661.66 347
PY2020 $116,376.14 146
PY2021 $57,679.99 73
PY2022 $41,184.88 64
PY2023 $17,080.11 53
PY2024 $20,064.39 29
PY2025 $19,376.17 45

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $441,079.70 291
PY2024 Principal investigator $488,241.43 318
PY2023 Principal investigator $338,591.22 78
PY2022 Principal investigator $309,620.67 112
PY2021 Principal investigator $338,390.99 210
PY2020 Principal investigator $26,804.41 9
PY2019 Principal investigator $16,541.33 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

291 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 United Therapeutics Corporation $1,605.12 12/24/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385067
Principal investigator 1 United Therapeutics Corporation $1,605.12 12/24/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385087
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 12/17/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716625
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 12/17/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716627
Principal investigator 1 Boehringer Ingelheim International GmbH $183.21 12/17/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716629
Principal investigator 1 Boehringer Ingelheim International GmbH $69.60 12/17/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716631
Principal investigator 1 Boehringer Ingelheim International GmbH $61.92 12/17/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716633
Principal investigator 1 United Therapeutics Corporation $950.00 12/17/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385115
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,710.70 12/15/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806873
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $360.00 12/15/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806965
Principal investigator 1 Verona Pharma, Inc. $500.00 12/10/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
Verona No dispute reported 06/30/2026 1232891801
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,517.00 12/05/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806793
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 12/05/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806795
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 12/05/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806797
Principal investigator 1 GlaxoSmithKline, LLC. $13,500.00 12/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192163362
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $640.00 12/03/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806963
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 12/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716493
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 12/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716545
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 12/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716547
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15.00 12/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220806805
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 12/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806959
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 12/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806961
Principal investigator 1 United Therapeutics Corporation $1,436.16 11/26/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385065
Principal investigator 1 United Therapeutics Corporation $1,436.16 11/26/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385085
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,935.00 11/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806871
Principal investigator 1 United Therapeutics Corporation $950.00 11/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385117
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,966.00 11/18/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806801
Principal investigator 1 United Therapeutics Corporation $300.00 11/14/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385105
Principal investigator 1 United Therapeutics Corporation $4,730.88 11/12/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385079
Principal investigator 1 United Therapeutics Corporation $4,730.88 11/12/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385095
Principal investigator 1 Verona Pharma, Inc. $13,363.26 11/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
Verona No dispute reported 06/30/2026 1232891811
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $50.00 11/04/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806791
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 11/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716491
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 11/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716541
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 11/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716543
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15.00 11/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220806803
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 11/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806955
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 11/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806957
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,247.50 10/31/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON No dispute reported 06/30/2026 1185537862
Principal investigator 1 United Therapeutics Corporation $700.00 10/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385113
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,476.00 10/28/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806949
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 10/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716549
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 10/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716605
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 10/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716607
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 10/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716609
Principal investigator 1 Boehringer Ingelheim International GmbH $122.14 10/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716611
Principal investigator 1 Boehringer Ingelheim International GmbH $46.40 10/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716613
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 10/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716615
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 10/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716617
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 10/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716619
Principal investigator 1 Boehringer Ingelheim International GmbH $40.56 10/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716621
Principal investigator 1 Boehringer Ingelheim International GmbH $30.96 10/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716623
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $69.00 10/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806789
Principal investigator 1 SANOFI US SERVICES INC. $500.00 10/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1226091089
Principal investigator 1 Boehringer Ingelheim International GmbH $322.00 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716577
Principal investigator 1 Boehringer Ingelheim International GmbH $11.70 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716579
Principal investigator 1 Boehringer Ingelheim International GmbH $450.00 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716581
Principal investigator 1 Boehringer Ingelheim International GmbH $75.90 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716583
Principal investigator 1 Boehringer Ingelheim International GmbH $50.70 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716585
Principal investigator 1 Boehringer Ingelheim International GmbH $144.00 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716587
Principal investigator 1 Boehringer Ingelheim International GmbH $203.10 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716589
Principal investigator 1 Boehringer Ingelheim International GmbH $18.00 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716591
Principal investigator 1 Boehringer Ingelheim International GmbH $72.30 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716593
Principal investigator 1 Boehringer Ingelheim International GmbH $105.90 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716595
Principal investigator 1 Boehringer Ingelheim International GmbH $103.20 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716597
Principal investigator 1 Boehringer Ingelheim International GmbH $30.60 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716599
Principal investigator 1 Boehringer Ingelheim International GmbH $8,400.00 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716601
Principal investigator 1 Boehringer Ingelheim International GmbH $60.55 10/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis No dispute reported 06/30/2026 1220716603
Principal investigator 1 Verona Pharma, Inc. $4,950.00 10/17/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
Verona No dispute reported 06/30/2026 1232891799
Principal investigator 1 United Therapeutics Corporation $300.00 10/08/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385107
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,831.00 10/06/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806787
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 10/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716489
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 10/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716537
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 10/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716539
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 10/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806941
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 10/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806943
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.00 10/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806945
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,110.40 10/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806947
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 10/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806951
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 10/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806953
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 09/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716535
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,723.10 09/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806799
Principal investigator 1 Verona Pharma, Inc. $15,000.00 09/24/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
Verona No dispute reported 06/30/2026 1232891645
Principal investigator 1 Verona Pharma, Inc. $2,000.00 09/24/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
Verona No dispute reported 06/30/2026 1232891647
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $179.80 09/23/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806869
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $50.00 09/18/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806785
Principal investigator 1 United Therapeutics Corporation $1,000.00 09/17/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385119
Principal investigator 1 Verona Pharma, Inc. $2,500.00 09/17/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
Verona No dispute reported 06/30/2026 1232891649
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,900.00 09/04/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806831
Principal investigator 1 United Therapeutics Corporation $300.00 09/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385103
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 09/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716473
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 09/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716527
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 09/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716529
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 09/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806937
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 09/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806939
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 08/28/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806931
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $360.00 08/28/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806933
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,083.35 08/28/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806935
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 08/26/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716477
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 08/26/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716479
Principal investigator 1 Boehringer Ingelheim International GmbH $61.07 08/26/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716481
Principal investigator 1 Boehringer Ingelheim International GmbH $20.73 08/26/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716483
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 08/26/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716485
Principal investigator 1 Boehringer Ingelheim International GmbH $7.50 08/26/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716487
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 08/26/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716531
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716533
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $320.00 08/21/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806867
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,411.90 08/21/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806929
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,416.96 08/18/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806927
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $250.00 08/15/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806781
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 08/15/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806783
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,738.00 08/14/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806779
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,900.00 08/14/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806865
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 08/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716471
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 08/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716523
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716525
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $800.00 08/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806853
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $480.00 08/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806855
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $225.00 08/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806857
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $520.00 08/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806859
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $800.00 08/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806861
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 08/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806863
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 08/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806923
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 08/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806925
Principal investigator 1 United Therapeutics Corporation $4,276.80 08/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385125
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 07/30/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806913
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $277.50 07/30/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806915
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,600.00 07/30/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806917
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $280.00 07/30/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806919
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $480.00 07/30/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806921
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 07/28/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716475
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $760.00 07/15/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806907
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 07/14/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806773
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 07/14/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806775
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 07/14/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806777
Principal investigator 1 CSL Behring $1,250.00 07/11/2025 Non-covered Recipient Entity
Clinical Trials Center of Middle Tennessee, LLC
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1252665927
Principal investigator 1 United Therapeutics Corporation $300.00 07/11/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385101
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,630.00 07/10/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806771
Principal investigator 1 United Therapeutics Corporation $3,041.28 07/08/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385077
Principal investigator 1 United Therapeutics Corporation $3,041.28 07/08/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385093
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 07/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716469
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 07/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716519
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 07/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716521
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 07/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806909
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 07/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806911
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,382.52 06/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806829
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 06/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806849
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $40.00 06/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806851
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,476.00 06/24/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806905
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $640.00 06/20/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806903
Principal investigator 1 United Therapeutics Corporation $300.00 06/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385099
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $800.00 06/16/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806843
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $800.00 06/16/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806845
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $840.00 06/16/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806847
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,052.00 06/11/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806769
Principal investigator 1 United Therapeutics Corporation $2,534.40 06/11/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385075
Principal investigator 1 United Therapeutics Corporation $2,534.40 06/11/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385091
Principal investigator 1 United Therapeutics Corporation $600.00 06/11/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385111
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $50.00 06/10/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806767
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 06/06/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806765
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $920.00 06/06/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806901
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 06/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716447
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 06/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716513
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 06/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716515
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,562.00 06/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806763
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 06/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806897
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 06/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806899
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $50.00 05/28/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806761
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 05/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716451
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 05/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716453
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 05/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716455
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 05/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716457
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 05/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716517
Principal investigator 1 United Therapeutics Corporation $1,890.00 05/21/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385121
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,240.00 05/15/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806825
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,683.00 05/13/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806759
Principal investigator 1 Genentech, Inc. $4,928.00 05/13/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588552
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,863.90 05/09/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806889
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $640.00 05/07/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806839
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,008.20 05/07/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806841
Principal investigator 1 United Therapeutics Corporation $1,436.16 05/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385063
Principal investigator 1 United Therapeutics Corporation $1,960.20 05/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385071
Principal investigator 1 United Therapeutics Corporation $1,960.20 05/07/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385073
Principal investigator 1 Genentech, Inc. $3,777.00 05/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588526
Principal investigator 1 Genentech, Inc. $2,500.00 05/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588541
Principal investigator 1 Genentech, Inc. $2,464.00 05/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588545
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28.00 05/02/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806895
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 05/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716445
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 05/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716509
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 05/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716511
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 05/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806891
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 05/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806893
Principal investigator 1 AstraZeneca Pharmaceuticals LP $800.00 04/30/2025 Non-covered Recipient Entity
DIABETES AND ENDOCRINOLOGY ASSOCIATES OF STARK COUNTY, INC
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1185537854
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,153.68 04/23/2025 Non-covered Recipient Entity
DIABETES AND ENDOCRINOLOGY ASSOCIATES OF STARK COUNTY, INC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185537864
Principal investigator 1 Boehringer Ingelheim International GmbH $48.50 04/23/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716449
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 04/23/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716459
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 04/23/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716461
Principal investigator 1 Boehringer Ingelheim International GmbH $427.49 04/23/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716463
Principal investigator 1 Boehringer Ingelheim International GmbH $103.65 04/23/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716465
Principal investigator 1 Boehringer Ingelheim International GmbH $11.76 04/23/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716467
Principal investigator 1 United Therapeutics Corporation $1,436.16 04/23/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385083
Principal investigator 1 AstraZeneca Pharmaceuticals LP $45,603.68 04/22/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185537856
Principal investigator 1 Genentech, Inc. $2,464.00 04/22/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588522
Principal investigator 1 Genentech, Inc. $2,464.00 04/22/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588530
Principal investigator 1 Genentech, Inc. $130.00 04/22/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588533
Principal investigator 1 Genentech, Inc. $6,648.00 04/15/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588537
Principal investigator 1 Genentech, Inc. $1,200.00 04/10/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDD
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588549
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,459.01 04/09/2025 Non-covered Recipient Entity
DIABETES AND ENDOCRINOLOGY ASSOCIATES OF STARK COUNTY, INC
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185537848
Principal investigator 1 United Therapeutics Corporation $844.80 04/09/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385061
Principal investigator 1 United Therapeutics Corporation $844.80 04/09/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385081
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $520.00 04/08/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806879
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,640.00 04/08/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806881
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.00 04/08/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806883
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 04/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716443
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 04/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806827
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 04/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806885
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 04/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806887
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,574.14 03/27/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185537852
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 03/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716429
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 03/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716431
Principal investigator 1 Boehringer Ingelheim International GmbH $122.14 03/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716433
Principal investigator 1 Boehringer Ingelheim International GmbH $41.46 03/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716435
Principal investigator 1 Boehringer Ingelheim International GmbH $3.36 03/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716437
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 03/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716439
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 03/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716505
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 03/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716507
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,046.30 03/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806877
Principal investigator 1 United Therapeutics Corporation $300.00 03/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385097
Principal investigator 1 United Therapeutics Corporation $350.00 03/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385109
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,713.40 03/18/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220806875
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,910.70 03/11/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806835
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $250.00 03/11/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806837
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 03/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716423
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 03/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716659
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 03/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716661
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 03/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806819
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 03/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806821
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 03/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806823
Principal investigator 1 United Therapeutics Corporation $1,689.60 02/26/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385069
Principal investigator 1 United Therapeutics Corporation $1,689.60 02/26/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385089
Principal investigator 1 Boehringer Ingelheim International GmbH $81.62 02/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716497
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 02/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716499
Principal investigator 1 Boehringer Ingelheim International GmbH $6.72 02/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716501
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 02/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716503
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 02/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220716559
Principal investigator 1 Boehringer Ingelheim International GmbH $42.06 02/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220716561
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 02/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220716563
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 02/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220716565
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 02/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220716567
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 02/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220716569
Principal investigator 1 Boehringer Ingelheim International GmbH $4.80 02/25/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220716571
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,963.26 02/21/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185537850
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,425.90 02/12/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1185537858
Principal investigator 1 United Therapeutics Corporation $2,500.00 02/12/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385055
Principal investigator 1 United Therapeutics Corporation $2,787.84 02/12/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385057
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,871.00 02/10/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220806757
Principal investigator 1 Genentech, Inc. $7,057.00 02/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211588557
Principal investigator 1 United Therapeutics Corporation $10,400.00 02/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385127
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 02/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716421
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220716553
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 02/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220716555
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 02/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220716557
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716639
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716641
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 02/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716643
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 02/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716645
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 02/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716647
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 02/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716649
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 02/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806813
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 02/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806815
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 02/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806817
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,583.37 01/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185537860
Principal investigator 1 United Therapeutics Corporation $2,787.84 01/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242385059
Principal investigator 1 United Therapeutics Corporation $2,650.05 01/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) No dispute reported 06/30/2026 1242385123
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 01/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716425
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 01/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716427
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 01/27/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220716495
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,553.50 01/21/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220806833
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 01/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220716441
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220716551
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 01/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220716573
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 01/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220716575
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716635
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716637
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 01/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716651
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 01/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716653
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 01/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716655
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 01/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220716657
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 01/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806807
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 01/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806809
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34.00 01/01/2025 Non-covered Recipient Entity
Clinical Trials Center Of Middle Tennessee LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220806811